HC Wainwright set a $10.00 target price on Celldex Therapeutics (NASDAQ:CLDX) in a research note issued to investors on Friday. The firm currently has a buy rating on the biopharmaceutical company’s stock.
Several other analysts have also recently commented on CLDX. BidaskClub cut Celldex Therapeutics from a sell rating to a strong sell rating in a research report on Thursday, January 11th. WBB Securities restated a buy rating and issued a $10.00 target price on shares of Celldex Therapeutics in a research report on Wednesday, December 6th. Three research analysts have rated the stock with a sell rating, one has issued a hold rating and five have given a buy rating to the company’s stock. Celldex Therapeutics presently has an average rating of Hold and an average target price of $7.05.
Celldex Therapeutics (NASDAQ:CLDX) traded down $0.07 on Friday, reaching $2.38. The company had a trading volume of 1,801,655 shares, compared to its average volume of 1,127,176. Celldex Therapeutics has a 12-month low of $2.20 and a 12-month high of $3.94. The firm has a market cap of $333.16, a PE ratio of -2.36 and a beta of 2.57.
Institutional investors and hedge funds have recently bought and sold shares of the stock. Vanguard Group Inc. increased its position in shares of Celldex Therapeutics by 7.8% during the 2nd quarter. Vanguard Group Inc. now owns 9,774,858 shares of the biopharmaceutical company’s stock valued at $24,143,000 after purchasing an additional 708,095 shares during the period. Meditor Group Ltd increased its position in shares of Celldex Therapeutics by 8.8% during the 3rd quarter. Meditor Group Ltd now owns 6,312,700 shares of the biopharmaceutical company’s stock valued at $18,054,000 after purchasing an additional 512,700 shares during the period. Ameriprise Financial Inc. acquired a new position in shares of Celldex Therapeutics during the 2nd quarter valued at $943,000. Dimensional Fund Advisors LP increased its position in shares of Celldex Therapeutics by 69.0% during the 2nd quarter. Dimensional Fund Advisors LP now owns 832,186 shares of the biopharmaceutical company’s stock valued at $2,056,000 after purchasing an additional 339,639 shares during the period. Finally, Russell Investments Group Ltd. increased its position in shares of Celldex Therapeutics by 741.9% during the 3rd quarter. Russell Investments Group Ltd. now owns 352,511 shares of the biopharmaceutical company’s stock valued at $1,008,000 after purchasing an additional 310,638 shares during the period. Hedge funds and other institutional investors own 52.38% of the company’s stock.
TRADEMARK VIOLATION WARNING: This story was originally posted by Community Financial News and is the sole property of of Community Financial News. If you are accessing this story on another website, it was illegally copied and reposted in violation of U.S. & international copyright & trademark legislation. The correct version of this story can be viewed at https://www.com-unik.info/2018/02/10/hc-wainwright-analysts-give-celldex-therapeutics-cldx-a-10-00-price-target.html.
Celldex Therapeutics Company Profile
Celldex Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other diseases. Its lead drug Rintega (also referred to as rindopepimut and CDX-110) is a therapeutic vaccine, which is meant for the treatment of glioblastoma patients.
Receive News & Ratings for Celldex Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celldex Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.